nature portfolio

Corresponding author(s):	Paul C. Trippier
Last updated by author(s):	Mar 29, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

\sim				
<.	tat	ΙIC	:11	\sim

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
So	ftware and code
Poli	cy information about <u>availability of computer code</u>
Da	ata collection Topspin 4.4, Agilent MassHunter, SeeSAR 12.1

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our $\underline{\text{policy}}$

Prism 10, Image J, MestReNova-LITECDE, SeeSAR 12.1

Supporting Information includes experimental details, materials, methods, source data, characterization, supplementary figures, and 1H, 13C NMR spectra. Raw fid files are available on request to the corresponding author.

Human rese	arch part	ticipants			
Policy information	about <u>studies i</u>	s involving human research participants and Sex and Gender in Research.			
Reporting on sex	and gender	Not applicable			
Population characteristics		Not applicable			
Recruitment		Not applicable			
Ethics oversight		Not applicable			
Note that full informa	ote that full information on the approval of the study protocol must also be provided in the manuscript.				
Field-spe	ecific re	eporting			
Please select the o	ne below that i	is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
X Life sciences	E	Behavioural & social sciences			
For a reference copy of	the document with	th all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
1					
Lite scier	nces sti	udy design			
All studies must dis	sclose on these	se points even when the disclosure is negative.			
Sample size	No studies requiring sample size calculations. All experiments in at least duplicate or higher. See replication below.				
Data exclusions	Two experiments were excluded from the MG132 experiments as no effect was observed for PROTAC, MG132, or combination.				
Replication	Western blots represent at least two replicates. Cell viability experiments represent mean of at least three experiments run in triplicate.				
Randomization	Not applicable.				
Blinding	No blinding.				
D	C				
		pecific materials, systems and methods			
		rs about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Matorials 2. ov	norimontal	systems Methods			
Materials & experimental systems n/a Involved in the study		n/a Involved in the study			
Antibodies		ChIP-seq			
Eukaryotic cell lines		Flow cytometry			
	logy and archaed				
Animals ar	Animals and other organisms				
Antibodies					

Antibodies used

AKR1C3 (mouse mAb, 1:200, Sigma, A6229), AKR1C1/C2 (rabbit mAb, 1:500, Abcam, ab179448), ARv7 (rabbit mAb, 1:500, Abcam, ab198394) and actin (mouse mAb, 1:1,000, ThermoFisher, MA5-11869).

Validation See manufacturers website. And Mol. Cancer. Ther. 2018, 17, 1833-1845.

Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>

Cell line source(s) ATCC or Dr. Trevor Penning (LNCaP1C3, J Steroid Biochem Mol Biol 2012, 130, 7-15).

Authentication Authenticated by ATCC at time of purchase. Cell line passage use was limited to no greater than passage 9.

Mycoplasma contamination Cell lines tested negative for mycoplasma contamination using the MycoAlert mycoplasma detection kit as per the

manufacturer's instructions (Lonza, LT07-318)

Commonly misidentified lines (See ICLAC register)

No commonly misidentified cell lines were used herein.